New Delhi, June 13 -- Ovarian cancer is considered a recalcitrant disease with poor overall survival, partially related to advanced stage at diagnosis, given the lack of reliable or valid screening tests. While recent advances in therapy, including the Radical Surgery and use of targeted therapies, hold promise to enhance survival, 75 per cent of women diagnosed with invasive epithelial stage III disease, the most common presentation, will succumb to the disease within five years.

The average overall 5-year survival rates are approximately 48.6 per cent. Hence, there is a need to understand the modifiable risk factors for ovarian cancer.

In an interview with HT Lifestyle, Dr Harshit Shah, Associate Surgical Oncologist at Fortis Hospital...